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Neuroblastomas are childhood tumors with frequent fatal relapses
after induction treatment, which is related to tumor evolution with
additional genomic events. Our whole-genome sequencing data anal-
ysis revealed a high frequency of somatic cytosine > adenine (C > A)
substitutions in primary neuroblastoma tumors, whichwas associated
with poor survival. We showed that increased levels of C > A substi-
tutions correlate with copy number loss (CNL) of OGG1 or MUTYH.
Both genes encode DNA glycosylases that recognize 8-oxo-guanine
(8-oxoG) lesions as a first step of 8-oxoG repair. Tumor organoid
models with CNL of OGG1 or MUTYH show increased 8-oxoG levels
compared to wild-type cells. We used CRISPR-Cas9 genome editing to
create knockout clones of MUTYH and OGG1 in neuroblastoma cells.
Whole-genome sequencing of single-cellOGG1 andMUTYH knockout
clones identified an increased accumulation of C > A substitutions.
Mutational signature analysis of these OGG1 and MUTYH knockout
clones revealed enrichment for C > A signatures 18 and 36, respec-
tively. Clustering analysis showed that the knockout clones group
together with tumors containingOGG1 orMUTYH CNL. In conclusion,
we demonstrate that defects in 8-oxoG repair cause accumulation of
C > A substitutions in neuroblastoma, which contributes to mutagen-
esis and tumor evolution.
neuroblastoma | 8-oxo-guanine repair | MUTYH | OGG1 | mutational
signatures
Neuroblastoma is a childhood tumor of the peripheral sym-pathetic nervous system that accounts for 15% of childhood
cancer mortality (1). Survival rates vary between spontaneous re-
missions in the low-stage neuroblastoma tumors to less than 50%
survival in the high-stage patient group (2). Like other pediatric
cancer types, the number of somatic mutations in neuroblastoma
is relatively low compared to adult cancers (3). Relapsed neuro-
blastoma tumors have an increased mutational burden compared
to primary tumors and show recurrent alterations in, e.g., the
RAS-MAPK pathway (4, 5).
Over the last years, substitution patterns and mutational signa-
tures have been investigated in adult and pediatric cancer types (3,
6, 7). These mutational signatures are characteristic combinations
of substitutions in the context of neighboring bases (6). For some of
these mutational signatures, the underlying mutational process has
been described, while it is unknown for others (6, 8). In the ma-
jority of pediatric cancer types, cytosine > thymine substitutions are
most abundant, which has been linked to spontaneous deamination
of 5-methyl-cytosines and mutational signature 1 (3). Several
studies reported a higher frequency of cytosine > adenine (C > A)
substitutions in neuroblastoma (3, 7). C > A mutations can result
from defects in 8-oxo-guanine (8-oxoG) repair (9). 8-oxoG is one
of the most abundant DNA lesions generated by reactive oxygen
species (10–12). 8-oxoG can base pair with both a cytosine (C) and
an adenine (A). During replication, DNA polymerases can there-
fore insert an incorrect A opposite of 8-oxoG. In the next round of
replication, a thymine (T) will be inserted opposite the A, finally
resulting in a C > A substitution (13, 14). To combat reactive ox-
ygen species–induced DNA damage, 8-oxoG can be recognized by
the DNA glycosylases OGG1 and MUTYH when it forms a base
pair with a C or A, respectively. 8-oxoG repair is initiated by ex-
cision of 8-oxoG by OGG1 or excision of the wrongly inserted A
opposite 8-oxoG byMUTYH (Fig. 1). In addition, NUDT1 prevents
incorporation of 8-oxo-dGTP from the free nucleotide pool, by
hydrolysis of 8-oxo-dGTP to 8-oxo-GMP, which cannot be incor-
porated (13, 15, 16).
In this study, we identify increased accumulation of C > A
substitutions in high-risk neuroblastoma, resulting in a strong
contribution of mutational signature 18 and 36 in these tumors.
We show that neuroblastoma tumors with high C > A substitution
frequencies were enriched for copy number loss (CNL) of OGG1
and MUTYH. To mimic this phenotype, we used CRISPR-CAS9
to engineer defects in the 8-oxoG repair genes OGG1 and
MUTYH in neuroblastoma cells, resulting in an increased accu-
mulation of C > A substitutions in single-cell knockout clones and
a high contribution of C > A mutational signatures 18 and 36. In
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clustering analysis, these clones group together with neuroblas-
toma tumors withOGG1 orMUTYH CNL. Finally, we evaluated a
neuroblastoma relapse cohort and identified that 47% of alter-
ations in RAS-MAPK pathway genes were caused by C > A
substitutions. Taken together, our study identifies that defects in
the 8-oxoG repair pathway cause an accumulation of C > A
substitutions in neuroblastoma tumors, potentially leading to in-
creased adaptive capacity and tumor evolution.
Results
High Frequency of C > A Substitutions Correlate with Poor Prognosis in
Neuroblastoma. We determined the somatic frequency of each of
the six possible base substitutions in our whole-genome sequenc-
ing (WGS) data of 86 primary neuroblastoma tumor/normal pairs
(17). C > A substitutions were the most abundant base substitu-
tion type, including 14 tumors with a C > A substitution frequency
higher than 50% (Fig. 2A and SI Appendix, Fig. S1 A and B).
Since C > A substitutions have been suggested to also occur
from sequencing artifacts (18), we reanalyzed available Sanger
sequencing results to confirm the C > A substitutions on the
original tumor biopsies (17). Sanger sequencing validation of C >
A substitutions was similar to validation of other substitutions (SI
Appendix, Fig. S1C). In addition, C > A ratios were not enriched in
the control DNA (leukocytes) (SI Appendix, Fig. S1D). Finally,
similar levels of C >A substitutions were found in tumors and their
corresponding organoid cell lines (SI Appendix, Fig. S1E). There-
fore, we conclude that the C > A substitutions found in our tumor
cohort were authentic.
We next compared the C > A substitution frequencies for the
different tumor stages and identified significantly more C > A
substitutions in International Neuroblastoma Staging System
(INSS) stage 4 tumors compared to the low-stage tumors (unpaired
t test with Welch correction, two-sided, P < 0.0001; Fig. 2B).
Furthermore, a Kaplan-Meier analysis indicates a significant log-
rank (P = 2.8 × 10−10) difference in overall survival between pa-
tients with a high and a low percentage of C > A substitutions
(Fig. 2C), independent of the prognostic factors of age, MYCN
status, and INSS stage (SI Appendix, Table S1). These results show
that the frequency of C > A substitutions is strongly increased in
neuroblastoma tumors and that this correlates with a poor
prognosis.
High Levels of C> A Substitutions Correlate with Defects inMUTYH and
OGG1. C > A substitutions can result from defects in the 8-oxoG
repair pathway (9). Therefore, we analyzed WGS data of our
neuroblastoma cohort for CNL and mutation status of MUTYH,
OGG1, and NUDT1. In a subset of tumors, we could identify CNL
of MUTYH or OGG1 (SI Appendix, Fig. S2 A and B). OGG1 is
located on 3p.25, which is part of the frequently deleted 3p region in
neuroblastoma.MUTYH, which is located on 1p.34, was deleted in a
subset of tumors with (partial) 1p CNL.NUDT1CNL was identified
in two tumors, which also had a MUTYH CNL (SI Appendix, Table
S2). CNL of OGG1 and MUTYH was associated with a high fre-
quency of C >A substitutions (Fig. 3A). Compared to tumors with a
normal copy number of OGG1 or MUTYH, a significantly higher
C > A substitution frequency is detected in tumors with CNL of
MUTYH (unpaired t test with Welch correction, two-sided, P <
0.0001) or OGG1 (unpaired t test with Welch correction, two-sided,
P = 0.0418; Fig. 3B). The tumor (N170T) with the highest C > A
substitution frequency (82%) carried a germline missense variant in
MUTYH (NP_036354.1:p.Ala425Pro) and a CNL of the other
MUTYH allele (SI Appendix, Table S2). This missense variant in
N170T is not reported in the Single Nucleotide Polymorphism
Database (dbSNP) (build 153). In addition, this mutation results in
an amino acid change from an alanine to a proline, which may
affect the protein conformation, although PolyPhen and SIFT do
not predict the variant to be damaging. Another tumor (N701T)
with a very high frequency (78%) of C > A substitutions carried a
germline missense variant in OGG1 (NP_002533.1:p.Gly308Glu)
and a CNL of the other OGG1 allele (SI Appendix, Table S2). For
this missense variant, it is predicted that it affects function. Overall,
five of the seven tumors with the highest C > A substitution fre-
quencies have multiple alterations in genes of the 8-oxoG repair
pathway (SI Appendix, Table S2). These results show that C > A
substitution frequencies are increased in neuroblastoma tumors
with OGG1 or MUTYH CNL.
8-oxoG Levels Are Increased in Cell Lines with Defects in MUTYH and
OGG1. To study the relation between 8-oxoG levels and defects in
the 8-oxoG repair pathway, we used modified alkaline comet as-
says (19). In this assay, cells embedded in agarose are lysed and
treated with purified recombinant OGG1, which creates DNA
nicks where 8-oxoG is present. Subsequent gel electrophoresis will
separate the nicked DNA from undamaged DNA. With this assay,
the DNA can be visualized as comets (undamaged DNA) and tails
(nicked DNA). The average tail moment can be used as a measure
for the induced DNA damage and therefore for the amount of
8-oxoG. For some of the tumors, we have established tumor-
derived organoid cultures (20), and similar C > A substitution
percentages were identified in the organoids compared to the
corresponding tumor (SI Appendix, Fig. S1D). Compared to a
wild-type organoid, two organoids with a defect in the 8-oxoG
repair pathway show significantly longer comet tails (unpaired
t test with Welch correction, two-sided, P < 0.0001), indicative of
higher levels of 8-oxoG (Fig. 4A and SI Appendix, Fig. S3A). To
show that the increased levels of 8-oxoG are indeed caused by the
defects in OGG1 and MUTYH, we performed rescue experiments
by inducing overexpression of wild-type OGG1 or MUTYH in
neuroblastoma cell lines with CNL of OGG1 or MUTYH, re-
spectively. Indeed, we could rescue high levels of 8-oxoG by
overexpression (72 h) of wild-type OGG1 or MUTYH, as indi-
cated by a significant decrease in comet tail size (unpaired t test
with Welch correction, P < 0.0001; Fig. 4 B and C and SI Ap-
pendix, Fig. S3 B and C). In a neuroblastoma tumor (N701T) with
one of the highest C > A mutation frequencies, a germline OGG1
Fig. 1. Schematic overview of 8-oxoG repair pathway. When a G in the DNA
is oxidized to an 8-oxo-guanine [8-oxoG(8)], the replicative DNA polymerases
will insert an A opposite of the 8-oxoG during replication. In the next round
of replication, a T will be inserted opposite of the A, resulting in a C > A
substitution. The DNA glycosylases OGG1 and MUTYH are able to recognize
8-oxoG base pairing with a C or A, respectively. OGG1 excises 8-oxoG from
the DNA, while MUTYH excises the A opposite of the 8-oxoG. The DNA is
further repaired by the base excision repair pathway to a C:G base pair for
OGG1-initiated repair or to a C:8-oxoG for MUTYH-initiated repair. This C:8-
oxoG base pair is then again a substrate for OGG1. In addition, NUDT1
prevents the incorporation of 8-oxo-dGTP into the DNA, by hydrolyzing
8-oxo-dGTP, from the free nucleotide pool, to 8-oxo-dGMP.
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missense variant was identified, as mentioned above. To test
whether this mutation in OGG1 is indeed inactivating, we also
induced overexpression of OGG1 containing the missense variant
(p.G308E) in the neuroblastoma cell line with OGG1 CNL. Since
overexpression of this variant increases the tail moment, this
shows that this variant does not rescue the levels of 8-oxoG (SI
Appendix, Fig. S4 A and B), confirming that this is an inactivating
event in OGG1. In addition, we also tested the effect of a germline
MUTYH missense variant identified in the tumor with the highest
C > A substitution frequency (N170T). Induced overexpression of
MUTYH containing this missense variant (p.A425P) in the neu-
roblastoma cell line with MUTYH CNL, resulted in a lower tail
moment compared to the uninduced control (SI Appendix, Fig.
S4 C and D). Nevertheless, the tail moment remains higher than
for induced overexpression without recombinant OGG1. This in-
dicates that this variant does not rescue the levels of 8-oxoG to a
similar extent as wild-type MUTYH and suggests that this variant
reduces MUTYH activity. Overall, these results indicate that
8-oxoG levels are increased in neuroblastoma organoids and cell
lines with defects in MUTYH and OGG1 and that this can be
rescued by overexpression of the affected wild-type gene.
Increased Accumulation of C > A Substitutions upon OGG1 or MUTYH
Knockout in Neuroblastoma Cell Line. To validate the correlation
between C > A substitutions and defects in the 8-oxoG pathway,
we created CRISPR-Cas9 knockout clones of MUTYH, OGG1,
A
B C
Fig. 2. High percentages of C > A substitutions in neuroblastoma are correlated with high-stage disease and poor prognosis. (A) Relative substitution frequency
of the six possible nucleotide substitutions, indicated with different colors, in a cohort of 86 neuroblastoma tumors. Tumors are ranked from left to right on C > A
substitution frequency. (B) Dot-boxplot presenting the C > A substitution frequency for the different stages of neuroblastoma (INSS, st1 = stage1, st2 = stage2,
st3 = stage 3, st4 = stage 4, st4s = stage 4s) in the same cohort. C > A substitution frequency is significantly higher (unpaired t test with Welch correction, two-
sided) in stage 4 neuroblastoma compared to lower stages. ****P < 0.0001. The central line in the boxplot indicates the median and the box limits indicate the
first and third quartile. The whiskers denote the interval within 1.5 times the interquartile range of the median. Outliers are indicated with a cross. The number of
patients per stage is indicated below the graph. (C) Kaplan–Meier curve was created using Kaplan scanning for the optimal curves. This curve indicates a sig-
nificantly worse survival for patients with high compared to low C > A substitution frequency (Bonferroni-corrected P = 2.8 × 10−10).
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or NUDT1 in a neuroblastoma cell line (CHP134). To create
these knockout clones, we inserted a puromycin resistance cas-
sette in one of the first exons of these genes to disturb the open
reading frame (Fig. 5A) (21). After puromycin selection, we
performed single-cell fluorescence-activated cell sorting (FACS)
to create knockout clones (Fig. 5B). Knockout clones were
genotyped and biallelic editing was confirmed for all selected
clones (SI Appendix, Fig. S5A). The selected clones also showed
absent expression of the targeted protein (Fig. 5C). Messenger
RNA expression of the target gene was also strongly reduced for
MUTYH and NUDT1 but only slightly reduced for OGG1, pos-
sibly because of inefficient nonsense-mediated decay of OGG1
(SI Appendix, Fig. S5 B–D). Selected knockout and wild-type
clones were passaged for a period between 88 and 126 d to ac-
cumulate independent mutations and subsequently single-cell
FACS sorted to establish subclones. From both clones and sub-
clones (n = 2 per gene), genomic DNA was isolated and subjected
to WGS to study the mutational patterns that accumulate between
the two clonal steps (SI Appendix, Table S3). MUTYH and OGG1
knockout clones showed a relative higher contribution of C > A
substitutions ranging from 43 to 57% compared to 25 to 30% in
control clones (Fig. 6A and SI Appendix, Table S3). This difference
was statistically significant for theMUTYH knockout clones versus
the wild-type clones (unpaired t-test, two tailed, P:0.0076) and the
MUTYH knockout clones and OGG1 knockout clones versus the
wild-type clones (unpaired t test, two-tailed, P: 0.0086). Also, the
total number of base substitutions per genome per day was in-
creased forMUTYH and OGG1 knockout clones compared to the
wild-type clones (SI Appendix, Fig. S6A). The substitution fre-
quencies in the NUDT1 knockout clones were similar to the wild-
type clones (Fig. 6A). No consistent changes in the number of
small insertions and deletions were identified between the dif-
ferent knockout and wild-type clones (SI Appendix, Fig. S6B).
These results indicate that knockout of OGG1 and MUTYH, but
not NUDT1, increases the accumulation of C > A substitutions in
individual neuroblastoma cells.
Mutational Signatures Analysis in Knockout Lines and Neuroblastoma
Tumors. To further study the mutational patterns of the different
knockouts, mutational spectra were analyzed and the relative
contributions of mutation signatures were determined. The mu-
tational spectra of the wild-type and knockout clones were visu-
alized by showing the relative contribution of the six possible
substitutions in their trinucleotide context (Fig. 6B). Cosine sim-
ilarity analysis showed that the mutational spectra of the MUTYH
and OGG1 knockouts are slightly different but cluster close to-
gether and separately from the wild-type and NUDT1 knockouts
(SI Appendix, Fig. S7A). The mutational spectra were compared
using the COSMIC SigProfiler signatures (6, 22). The OGG1
knockouts have an increased number of C > A substitutions at the
trinucleotide contexts characteristic of signature 18, relative to the
wild-type clones. The slightly different pattern of the MUTYH
knockouts mimics the mutational signature 36 (Fig. 6B and SI
Appendix, Fig. S7B).
To relate the mutational spectra of the knockout clones to
primary tumor samples, combined relative signature contributions
were determined and plotted in a heatmap (Fig. 7). There is a
strong contribution of signature 36 in one of the tumors, which
clusters with the MUTYH knockout clones (Fig. 7). This tumor
(N170T) is the only tumor with both a germlineMUTYHmissense
variant and CNL of the other MUTYH allele. In addition, a large
cluster with a high contribution of signature 18 was identified in
our neuroblastoma tumor cohort. These tumors cluster together
with the OGG1 knockout clones (Fig. 7). More than 60% of the
tumors in this cluster harbor OGG1 or MUTYH CNL. Further-
more, signature 18 or signature 36 has the highest relative con-
tribution in 90% of the tumors with OGG1 or MUTYH CNL,
while this is only 31% in tumors without defective 8-oxoG repair.
Overall, these results indicate that the OGG1 and MUTYH
knockout clones have a high contribution of C > A mutational
signatures 18 and 36, respectively, and cluster together with neu-
roblastoma tumors with OGG1 or MUTYH CNL.
Clinical Relevance of Defects in 8-oxoG Repair in Neuroblastoma. To
investigate potential therapeutic strategies for defects in the
8-oxoG repair pathway, we performed a compound screen (∼330
compounds; SI Appendix, Table S4 A and B) with the OGG1,
MUTYH, and NUDT1 knockout CHP134 clones. No differential
sensitivities compared to the CHP134 mother line were identi-
fied (SI Appendix, Fig. S8 A and B). These results indicate that
defects in OGG1, MUTYH, and NUDT1 do not render CHP134
B
A
Fig. 3. High frequency of C > A substitutions correlates with loss of MUTYH
or OGG1. (A) The circular binary segmentation (CBS) scores for MUTYH and
OGG1 are plotted for 86 neuroblastoma tumors. The dots represent indi-
vidual tumor samples and are colored for relative C > A substitution fre-
quency as indicated in the color scale. The red and brown dashed line
indicate the cutoff (CBS < −0.5) for MUTYH CNL and OGG1 CNL, respectively.
(B) Dot-boxplot presenting the C > A substitution frequency for neuroblas-
toma tumors withMUTYH CNL (CBS < −0.5), OGG1 CNL (CBS < −0.5), or wild-
type (MUTYH and OGG1 CBS > −0.5). The number of tumors per group is
indicated below the graph. C > A substitution frequency is significantly
higher (unpaired t test with Welch correction, two-sided) in neuroblastoma
tumors with MUTYH CNL or OGG1 CNL compared to wild-type. ****P <
0.0001, *P < 0.05. The central line in the boxplot indicates the median and
the box limits indicate the first and third quartile. The whiskers denote the
interval within 1.5 times the interquartile range of the median. Outliers are
indicated with a cross.
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cells more sensitive to chemotherapeutics and targeted com-
pounds. The high frequency of C > A substitutions in neuroblas-
toma might contribute to the adaptive capacity of the tumors. We
evaluated a previously published dataset of primary and relapse
neuroblastoma tumors (4). In this cohort of 23 primary-relapse
neuroblastoma tumor pairs, 7 of the 15 tumor evolution events in
the RAS-MAPK pathway were C > A substitutions (SI Appendix,
Table S5) (4). This indicates that in this small dataset, 47% of the
known single-nucleotide variants (SNVs) involved in tumor evo-
lution are C > A substitutions.
Discussion
For the majority of pediatric tumors, the most prevalent substitution
type is C > T (3). However, C > A substitutions are the most fre-
quent substitution type in neuroblastoma (3, 7). Here, we show that
defects in the 8-oxoG repair pathway result in high levels of C > A
substitutions in neuroblastoma tumors, which is correlated with a
poor prognosis. In concordance, knockout of OGG1 and MUTYH
results in increased accumulation of C > A substitutions in a neu-
roblastoma cell line. We identified a high contribution of C > A
mutational signatures 18 and 36 in the OGG1 and MUTYH
knockout clones, respectively, which cluster together with neuro-
blastoma tumors with OGG1 or MUTYH CNL.
CNL of MUTYH or OGG1 is common in neuroblastoma since
these genes are located on chromosome arms 1p and 3p, re-
spectively, which are recurrently lost in neuroblastoma (23, 24).
On the other hand, NUDT1 loss (located on 7p) is very rare and,
in our cohort, only identified in combination with MUTYH CNL.
Strikingly, five of the seven tumors with the highest C > A
substitution frequencies have multiple alterations in genes of the
8-oxoG repair pathway. This suggests that multiple alterations in
this pathway result in a cumulative effect on the C > A substi-
tution frequency. Other neuroblastoma tumors indicate that
partial loss of OGG1 or MUTYH can also be sufficient to induce
high C > A substitution levels.
We confirmed the effect of defective 8-oxoG repair on the C >
A substitution levels in a neuroblastoma cell line. As expected,
MUTYH and OGG1 knockout clones showed increased accu-
mulation of C > A substitutions. Most neuroblastoma tumors
show heterozygous loss instead of homozygous loss of OGG1 or
MUTYH, which we expect to result in a similar but more modest
phenotype. The NUDT1 knockout clones did not show an in-
crease in C > A substitutions compared to the wild-type clones.
NUDT1 prevents the incorporation of 8-oxoG into the DNA.
Although 8-oxoG can base pair with both a C and an A, the
insertion opposite of an A is expected to be most mutagenic
since this will result in A > C (T > G) substitutions, while in-
sertion opposite of a C can be repaired by OGG1. Nevertheless,
the mutational spectrum of the NUDT1 knockouts is similar to
the wild-type clones, and no increase in T > G substitutions has
been detected. This substantiates previous results of NUDT1
knockout in HAP1 cells, which also did not produce detectable
mutational signatures compared to the parental clone (25).
The mutational signature analysis in the knockout clones
identified a strong contribution of mutational signatures 18 and 36
in the OGG1 and MUTYH knockout clones, respectively. These
similar signatures both mainly consist of C > A substitutions, al-
though with a slightly different trinucleotide distribution (9, 26,
27). Signature 36 was discovered in tumors of patients with
MUTYH-associated polyposis but has not been described in neu-
roblastoma tumors (9, 27). A strong contribution of signature 36
was identified in only one of the neuroblastoma tumors, which
contains a MUTYH missense variant and MUTYH CNL. This
suggest that only if both MUTYH alleles are affected, this results in
signature 36, similar to the biallelic variants in patients with
MUTYH-associated polyposis. Signature 18 was previously identi-
fied to be common in neuroblastoma (3, 6, 7, 28, 29). In our cohort
of neuroblastoma, signature 18 was also identified as a common
signature in a cluster of tumors with frequent CNL of OGG1 or
MUTYH (>60% of the tumors). These results confirm the corre-
lation between signatures 18 and 36 and defects in the 8-oxoG re-
pair pathway. In concordance, a Nudt1/Ogg1/Mutyh triple knockout
mouse model accumulates C > A substitutions with a mutational
pattern that is highly similar to signature 18 or 36 (9, 27, 30). In
addition, the study of Brady et al. also identified that tumors with 1p
CNL have a significant higher number of substitutions caused by
signature 18, while for 3p loss a similar trend was visible (29).
Although in our cohort, most tumors with high C > A substi-
tution frequencies and high contribution of signature 18 have a
loss of OGG1 or MUTYH, there are also some tumors with a
similar pattern that lack defects in this pathway. This suggests that
other factors might play a role. Interestingly, the study of Brady
A B C
Fig. 4. Defects in the 8-oxoG repair pathway result in higher 8-oxoG levels. Tail moments were calculated from modified comet assays with [red bar (+)] or
without [blue bar (−)] recombinant OGG1 (rOGG1) treatment. (A) Modified comet assays were performed for two organoids with defects in the 8-oxoG
pathway (AMC717T with MUTYH CNL, AMC700T with OGG1 CNL) and one organoid with a functional 8-oxoG pathway (AMC691T). (B, Upper) OGG1 protein
expression in SJNB12 (with OGG1 CNL) transduced with a pIND-OGG1 vector with (+) or without (−) addition of doxycycline (Dox). β-actin is used as a loading
control. (Lower) Tail moments calculated from modified comet assays for SJNB12 with (+) or without (−) Dox-induced OGG1 overexpression. (C, Upper)
MUTYH protein expression in SJNB10 (with MUTYH CNL) transduced with a pIND-MUTYH + or − Dox. β-actin is used as a loading control. (Lower) Tail
moments calculated from modified comet assays for SJNB10 with (+) or without (−) Dox-inducedMUTYH overexpression. Error bars indicate the SEM. P values
are calculated with unpaired t test with Welch correction, two-sided, ****P < 0.0001, **P < 0.01, *P < 0.05.
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et al. identified enrichment of signature 18 in neuroblastomas
with MYCN amplification, 17q gain and increased expression of
mitochondrial ribosome and electron transport–associated
genes (29). Additionally, the level of endogenous oxidative
stress might influence whether tumors accumulate high levels
of C > A substitutions or not.
The functional consequence of the high frequency of C > A
substitutions might lie in the increased adaptive capacity of the
tumors. In a previous study, RAS-MAPK alterations, which are
enriched in relapsed neuroblastoma, were C > A substitutions in 7
of 15 neuroblastoma tumors with an alteration in this pathway (4,
31). Although this cohort is small, this suggests that C > A sub-
stitutions caused by defects in the 8-oxoG repair pathway might
influence tumor evolution. Supporting this, Brady et al. showed
that in their cohort 52% of driver gene mutations were most likely
induced by signature 18, making this the most common cause of
driver point mutations in neuroblastoma (29). We propose a tu-
mor evolution model in which early neuroblastoma tumor clones
acquire chromosomal aberrations (1p, 3p) that lead to defects in
8-oxoG repair. Subsequently, these tumor cells show an increased
frequency of signature 18 and 36 related genomic aberrations that
lead to additional defects in tumor evolution associated pathways
like RAS-MAPK and ALK.
Although defects in the 8-oxoG repair pathway result in C > A
substitutions, no genomic instability is expected, making it unlikely
that these defects alter compound sensitivity. As we expected, no
differential sensitivities between the OGG1, MUTYH, or NUDT1
knockout cells and the CHP134 mother line were identified in our
compound screens. We conclude that the C > A substitution
phenotype does not function as biomarker for targeted compound
intervention to our current knowledge. However, the potential
role of this mutational process in tumor evolution in neuroblas-
toma could select these tumors for ALK or MEK inhibitors (4).
Overall, we identified that defects in the 8-oxoG repair path-
way result in high levels of C > A substitutions in neuroblastoma
cell line models and tumors. These high levels of C > A substi-
tutions correlate with a poor prognosis, possibly related to an
increased adaptive capacity of these tumors.
Methods
WGS of 86 neuroblastoma tumors was previously performed (17), and per-
centages of the six possible substitutions were calculated with the actual
observations (not corrected for genome distribution). Modified comets as-
says with neuroblastoma cell lines and organoids were performed as de-
scribed previously (19). To create knockouts of MUTYH, OGG1, or NUDT1 in
the CHP134 neuroblastoma cell line, cells were transfected with the guide RNA




Fig. 5. CRISPR-Cas9 editing and clonal selection ofMUTYH, OGG1, and NUDT1 knockout (sub)clones in CHP134 cell line. (A) CRISPR-Cas9 editing strategy used
for targeting MUTYH, OGG1, or NUDT1 in CHP134. (B) Schematic overview of the strategy used for creating clones and subclones of CRISPR-Cas9–edited and
wild-type CHP134. Both clones and subclones were sent for WGS to evaluate the mutations that accumulate during clonal outgrowth. (C) Western blot
analysis of MUTYH expression in wild-type and selected MUTYH knockout clones of CHP134. GAPDH is used as a loading control. (D) Western blot analysis of
OGG1 expression in wild-type and selected OGG1 knockout clones of CHP134. α-tubulin is used as a loading control. (E) Western blot analysis of NUDT1
expression in wild-type and selected NUDT1 knockout clones of CHP134. α-tubulin is used as a loading control.
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corresponding homology arm vector (in pJET1.2/blunt vector) to disrupt the
open reading frame with a puromycin resistance cassette (21). From clonal and
subclonal cultures with confirmed knockout, DNA was isolated and sent for
WGS. Mutational landscapes in the mutant clones were explored using an
in-house developed R package (MutationalPatterns) (32). To identify
mutational signature contributions, the COSMIC SigProfiler signatures
A
B
Fig. 6. MUTYH or OGG1 knockout results in accumulation of C > A substitutions in neuroblastoma cell line. (A) Relative substitutions per genome per day
that accumulated in MUTYH knockout, OGG1 knockout, NUDT1 knockout, and wild-type CHP134 clones. Substitution types are indicated with colors. (B)
Mutational spectra are displayed according to the 96 substitution types defined by the substitution class and its trinucleotide context for the different
knockout and wild-type clones. The substitution types are indicated on the x-axis, and the relative contribution of the substitution type is depicted on the
y-axis.
van den Boogaard et al. PNAS | 7 of 9
























































Fig. 7. Mutational signatures in neuroblastoma tumors and CHP134 (knockout) clones. Heatmap of neuroblastoma tumors and CHP134 (knockout) clones
showing the relative signature contributions for the COSMIC Single Base Substitutions signatures (indicated below the heatmap). Samples have been
clustered according to their relative signature contributions. CHP134 clones are indicated in bold. Signature contributions scores are colored as indicated
in the color key on the top left. The right panel shows properties of the patient/tumor (MYCN status, status [alive or death of disease], INSS stage, MUTYH
status, and OGG1 status) represented by color as indicated in the legend below. KO means knockout. A germline mutation in MUTYH or OGG1 is indicated
with a G.
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(https://www.synapse.org/#!Synapse:syn11967914) were refitted to the
obtained mutational profiles for all the clones and tumor samples, and their
relative contributions were calculated (excluding low contributing signatures).
SI Appendix, Extended Materials and Methods includes additional
experimental details.
Data Availability. WGS data of the neuroblastoma tumor cohort has been de-
posited at the European Genome-Phenome Archive (EGA, http://www.ebi.ac.uk/
ega/), which is hosted by the EBI, under accession number EGAS00001000222 (33).
WGS data of the clones created in this study is available at Sequence Read Archive
(https://www.ncbi.nlm.nih.gov/sra/) under accession number PRJNA721261 (34).
The raw data of other experiments will be available upon request.
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